Apr 09, 2018 - Incyte Corp. (INCY) and Merck (MRK) announced Friday morning that their Phase 3 study of Incyte's epacadostat in combination with Merck's KEYTRUDA did not meet the primary endpoint.
Apr 09, 2018 - Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
Apr 06, 2018 - The failure of an important trial casts doubt on the future of combination immunotherapy.
Apr 06, 2018 - On a day stocks plunged, Incyte crashed following a failed drug trial and PriceSmart moved up after reporting rising sales.
Apr 06, 2018 - A high-profile flop for a once-promising cancer drug in development at Incyte is sparking fear across the industry.
Apr 06, 2018 - There's bad news on the clinical trial front.
Apr 06, 2018 - Incyte (INCY 68.00, -15.07, -18.1%) and Merck (MRK
53.84, -0.68, -1.3%), known as MSD outside the Un
Apr 05, 2018 - Barclays issues rating change for INCY
Apr 02, 2018 - The short argument against Geron doesn't add up. Here's why.
Mar 28, 2018 - April showers might bring May flowers. But they also bring major FDA decisions for these biotechs.